Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Victoria Mateos

Showing results (181-190 of 211) with videos related to

Pageof 22
Sort By:
Blood Advances|November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myelomaInés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Leukemia|December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosisNoemi Puig, Bruno Paiva, Marta Lasa, et al.
Leukemia|June 2, 2020
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaJuan-José Garcés, Gabriel Bretones, Leire Burgos, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Pageof 22

Showing results (181-190 of 211) with videos related to

Sort By:
Pageof 22
Blood Advances|November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myelomaInés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Leukemia|December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosisNoemi Puig, Bruno Paiva, Marta Lasa, et al.
Leukemia|June 2, 2020
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaJuan-José Garcés, Gabriel Bretones, Leire Burgos, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Cancer Cell|November 15, 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myelomaRomanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, et al.
Pageof 22